Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)
Allogene Therapeutics (ALLO) reported Current Deferred Revenue of $86000.0 for Q1 2024, little changed on a YoY basis from $86000.0 in Q2 2023, and little changed sequentially from $86000.0 in Q4 2023.
Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024) Analysis & Trends
Allogene Therapeutics (ALLO) has 5 years of Current Deferred Revenue data on file, last reported at $86000.0 in Q1 2024.
- For the quarter ending Q1 2024, Current Deferred Revenue changed 0.0% year-over-year to $86000.0; the trailing twelve-month figure through Mar 2024 stood at $86000.0 (changed 0.0% YoY), and the FY2023 full-year result was $86000.0, down 9.47% from the prior year.
- Current Deferred Revenue held at $86000.0 in Q1 2024, from $86000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $39.0 million in Q4 2020 to a low of $86000.0 in Q1 2023.
- A 5-year average of $2.9 million and a median of $101500.0 in 2022 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue plunged 99.6% in 2021 and changed 0.0% in 2024, its largest moves.
- Tracing ALLO's Current Deferred Revenue over 5 years: stood at $39.0 million in 2020, then tumbled by 99.6% to $156000.0 in 2021, then plunged by 39.1% to $95000.0 in 2022, then fell by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
- Business Quant data shows ALLO's Current Deferred Revenue at $86000.0 in Q1 2024, $86000.0 in Q4 2023, and $86000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Sep 30, 2023 | 86,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | 86,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 104,000.00 |
| Mar 31, 2022 | 147,000.00 |
| Dec 31, 2021 | 156,000.00 |
| Sep 30, 2021 | 365,000.00 |
| Jun 30, 2021 | 305,000.00 |
| Mar 31, 2021 | 239,000.00 |
| Dec 31, 2020 | 38.99 Mn |